First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kournoutas Ioannis, Marell Paulina, Gile Jennifer, Peersen Anina, Shah Priyanshi, VanDommelen Kyle, Kamath Suneel D, Gupta Garima, Akce Mehmet, Yang Ju Dong, Chen Pin-Jung, Naleid Nikolas, Mahipal Amit, Peterson Nicole, Sahai Vaibhav, Wee Ma Wen, Jin Zhaohui, Halfdanarson Thorvardur, Fonkoua Kankeu Lionel, Washburn Leslie A, Conboy Caitlin B, Torbenson Michael, Goenka Ajit, Thompson Scott, Venkatesh Sudhakar K, Starlinger Patrick, Roberts Lewis, Gores Gregory J, Babiker Hani, Ahn Daniel, Borad Mitesh, Bekaii-Saab Tanios, Jatoi Aminah, McWilliams Robert R, Ou Fang-Shu, Tran Nguyen H
Аннотация
METHODS: We reviewed outcomes of patients with uHCC who initiated atezo/bev or durva/treme between 2017 and 2024, across six institutions. Overall survival (OS) and time to treatment discontinuation (TTD) were analyzed using the Kaplan-Meier and Cox models, adjusting for baseline characteristics.
RESULTS: Four hundred fifty-two uHCC pts were included. Median age: 68 years; 77% male; 81% white. Most common etiologies were viral hepatitis (38.9%) and metabolic dysfunction-associated steatohepatitis (19.5%). Disease progression was the primary reason for treatment discontinuation, atezo/bev (56%) and durva/treme (42%). Outcomes were not statistically significant (median OS [month, m]: 14.0 vs 14.6 [P = .66]; median TTD [m]: 4.9 vs 3.9 [P = .42] for atezo/bev vs durva/treme). Outcomes were significantly different between Child-Pugh classes (CP: A, B7, B8/9, C) respectively, median OS(m): 19.0, 6.1, 5.1, 2.0 (P < .001); median TTD(m): 6.1, 2.3, 3.0, 1.3 (P < .001).
CONCLUSIONS: In this real-world study of uHCC, no significant difference in clinical outcomes was observed between atezo/bev and durva/treme in the first-line setting. CP scores were a key prognostic variable with both regimens.